| Name | Title | Contact Details |
|---|
If you are looking for a seamless solution for all your patients needs, you have come to the right place. Whether it is Insurance Verification, Eligibility, Advanced Eligibility, Credit Balances, FrontRunnerHC has exactly what you are looking for
Grid Dynamics International, Inc. designs and builds massively scalable mission-critical systems. We help customers such as Cisco, PayPal, eBay, Macy’s, ING and Microsoft create systems and products that handle exceptional peak loads, scale on demand and always stay up. Using the latest advances in grid and cloud computing we turn monolithic software into scalable services and static, underutilized server farms into virtualized compute clouds. The results: better performance, higher availability, faster time-to-market and much lower operational costs. Our team consists of exceptionally passionate software engineers and scientists who love tackling difficult problems. Over the past seven years we have developed a track record for innovation and quality with nearly every one of our customers.
Business Success Management is a Edison, NJ-based company in the Software and Internet sector.
Features Analytics is a company that delivers AI-driven surveillance solutions for financial institutions, with a focus on proactively detecting and preventing market abuse and financial crime.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.